Bloomberg reported that Pfizer Inc. is planning to acquire Agila Specialties Private Limited for a possible price of $2 billion. Bloomberg reported citing unnamed sources that Pfizer is conducting due diligence on Agila and a formal deal could be reached in the first quarter of 2013. Reuters said that a Pfizer spokeswoman said that the company does not comment on market rumors.